Biocon Releases Q2 2026 Financial Results; Group Revenue Reaches 43,360 Million
Biocon Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The company's Board of Directors approved both the standalone and consolidated results, which were limitedly reviewed by statutory auditors.The consolidated figures showed a total income of 43,905 million in the quarter, with revenue derived from operations standing at 43,360 million. Net profit for the period stood at 1,368 million, while the total comprehensive income was reported at 9,256 million.
The standalone entity reported a revenue from operations of 6,245 million. Total income reached 6,893 million, before accounting for total expenses of 6,194 million. The company recorded a Net Profit/loss for the period of 522 million.
Segment Performance Highlights
The consolidated results highlight the operational breakdown across three main segments: Biosimilars, Generics, and Services.| Segment | Revenue from Continuing Operations (3 months ended 30.06.2026) | Profit before Tax from each segment |
|---|---|---|
| Biosimilars | 28,556 Million | 1,714 Million |
| Generics | 7,597 Million | (309) Million |
| Services | 7,360 Million | (57) Million |
Operational and Strategic Updates
The company announced several significant operational developments during the reporting period. The Board also recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- on May 07, 2026, which is subject to shareholder approval at the Annual General Meeting.In other related corporate actions, Syngene International Limited's Board of Directors recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-, pending shareholder approval in its Annual General Meeting. Furthermore, it was disclosed that Biocon International approved the voluntary liquidation of its wholly owned subsidiary, Syngene Manufacturing Limited, following shareholder approval on June 15, 2026.
Acquisition and Financial Highlights
The financial results encompass several major transactions undertaken by the company and the Group during the year ended March 31, 2026. These include the acquisition of 115,36,956 equity shares of BBL from a selling shareholder via a share swap transaction in Q2 2026. This process led to the allotment of 87,86,362 equity shares of Rs. 5 each, fully paid-up, at an issue price of Rs. 376.41 per share on June 29, 2026, making BBL a wholly owned subsidiary effective from that date.The unaudited financial results were reviewed by BSR & Co. LLP, Chartered Accountants.
BIOCON Stock Price Movement
Today, Biocon Limited shares edged higher to close at ₹425.2 after settling a gain of 0.76%. The stock saw a trading volume of roughly 3.30 million shares, having ranged between a low of ₹422.3 and a high of ₹428.65 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.